SHORT MINI-FUTURE - NOVO-NORDISK B | Market Closed - Bid/Ask 11:13:24 27/05/2024 pm IST | Pre-market 12:00:09 pm | |||
| 3.16 EUR | +5.33% |
|
3.29 | +4.11% |
| Current month | -8.67% | ||
| 1 month | -12.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 3.16 | +5.33% |
| 24/24/24 | 3 | +2.04% |
| 23/24/23 | 2.94 | -7.55% |
| 22/24/22 | 3.18 | +1.92% |
| 21/24/21 | 3.12 | -8.50% |
Real-time Boerse Frankfurt Warrants
Last update May 27, 2024 at 11:13 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XA3 |
| ISIN | DE000VD1XA39 |
| Date issued | 08/03/2024 |
| Strike | 1,164 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.59 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.35 € |
|---|---|
| Lowest since issue | 2.94 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
919.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.14%
- Stock Market
- Certificates
- Certificat
